Cycle science: Hormonal contraception and your body

By Maegan Boutot, Science Writer for Clue

Most American and European women will use at least one form of hormonal contraceptive, or birth control, at some point in their lives (1,2). They are most likely to have tried the oral contraceptive (OC) pill (1,2) and about 2 in 10 American and European women are current OC users (1–3).

Hormonal contraceptives are very effective at preventing unintended pregnancy (4). Between 0 to 9 in every 100 people relying on these will get pregnant over the course of a year, depending on which form of hormonal contraceptive they use (4). This number is lower in people who use hormonal contraceptives perfectly. In comparison, 18 in 100 people relying on male condoms will get pregnant over the course of a year (4). The implantable rod, or just the implant, is the most effective form of hormonal contraceptive (4) and is usually placed in your arm by your healthcare provider. Less than 1 in 100 people using this method will get pregnant over the course of a year (4).

Although hormonal contraceptives are highly reliable for preventing pregnancy, between roughly half and three quarters of American women who have used hormonal contraceptives have reported side effects that made them stop using them (1). Between roughly 2 to 4 in 10 hormonal contraceptive users from Western Europe have reported stopping due to side effects or worry over health effects (2).

If you choose to use a hormonal or non-hormonal contraceptive, it’s important to consider how effective, easy, beneficial or harmful each method might be for you. Not every form of hormonal contraceptive works the same, so one may be a better choice for you than another. Non-hormonal methods are another possibility for preventing unintended pregnancies. Both hormonal and non-hormonal forms of contraception have benefits and risks.

Biology of hormonal contraception

Methods of contraception can be classified as non-hormonal or hormonal. Non-hormonal forms of contraception, like condoms or the copper intrauterine device (IUD), don’t change the natural levels or functions of hormones within the body (4).

However, hormonal contraceptives change the normal levels of estrogen, progesterone, as well as other hormones (4).

*This graph is based on one generic type of combined hormonal contraceptive pill across the cycle. In reality, hormone levels will go up and down as pills are taken on a daily basis, and different pills contain a different hormonal make-up

Hormonal contraceptives usually contain alternate forms of estrogen and/or the synthetic form of progesterone called progestin (3,4).

People using the most common forms of hormonal contraception don’t ovulate. These methods stop the usual production patterns of reproductive hormones and prevent the ovaries from releasing eggs. They do this by stopping or changing the usual hormonal “cycling.” Exceptions include the “mini pill” and the levonorgestrel IUD. These methods work in a different way, but still prevent ovulation in some people (5).

Hormonal contraceptives that include both estrogen and progestin are:

  • Combined oral contraceptives (COCs)
  • Hormonal vaginal ring
  • Contraceptive patch (4)

Hormonal contraceptives that include only progestin are:

  • Progestin-only pills (the “mini-pill”) (POCs)
  • Contraceptive shot or injection (typically under the brand name Depo-Provera)
  • Implantable contraceptive rods (“the implant”)
  • Levonorgestrel (LNG) IUD (4,6)

Emergency contraception (i.e. “the morning after pill,” sometimes referred to by the brand name Plan B) also affects normal levels of estrogen and progesterone, either by increasing the amount of these hormones or interfering with proteins that interact with these hormones (4,6,7). Emergency contraception primarily works by blocking ovulation — it does not end a pregnancy after it has occurred (8). It’s not recommended for use as a primary method of birth control (4), but it is recommended in circumstances where contraception failed, contraception was used improperly or no contraception was used for the prevention of pregnancy. Using emergency contraception as needed is safe and is effective at preventing pregnancy if taken within 3–5 days, though it should be taken as soon as possible (9).

Physical side effects

Users of hormonal contraceptives report both positive and negative side effects.

Period bleeding is different when using most types of hormonal contraception, including COCs. The period changes from the typical shedding of the uterine lining, to a period-like bleeding, called withdrawal bleeding. Withdrawal bleeding happens in the week when pills contain no hormones, or in the time when a patch or vaginal ring is removed. Because withdrawal bleeding tends to be lighter than normal menstrual bleeding, hormonal contraceptives can reduce menstrual flow (10). People who experience heavy bleeding, prolonged bleeding, menstruation-related anemia or iron deficiency may benefit from hormonal contraceptives (10). These can also reduce painful menstruation, including pain caused by endometriosis (10).

People may also choose to use hormonal contraceptives to change their period’s regularity. Menstrual regulation is one of the top reasons people are prescribed hormonal contraceptives for reasons other than birth control (11). People can use this form of birth control to make periods more regular, induce periods or induce intentional amenorrhea (i.e. no periods) (11). This may be particularly useful for people with chronic reproductive problems, such as polycystic ovary syndrome (PCOS) (12).

Hormonal contraception can affect your skin. COCs are recommended for the treatment of acne (10,13), primarily due to the acne-reducing effects of estrogen. Conversely, the development of acne, melasma, or negative changes to the appearance of skin are also common side effects of hormonal contraception (14,15). These negative effects seem to be most strongly related to POCs, so switching to COCs or other forms of combined hormonal contraceptives may help fix these problems.

Nausea, headaches and breast tenderness are also commonly reported side effects (14,16), though there is evidence to suggest these side effects are strongest in new users and diminish over time (14,17). Hormonal contraceptives may also reduce breast tenderness with long term use (14).

Weight gain and changes to libido (sex drive) are concerns for many people taking hormonal contraceptives (14,16). However, other than the contraceptive shot, which has been found to increase weight in users (14), most research suggests the average hormonal contraceptive user experiences little or no change (14). Some people might notice their libido is higher or lower overall, though many people report no change (18). Hormonal fluctuations in a “normal” cycle also tend to create times of higher and lower libido (a higher sex drive is common leading up to and around the time of ovulation) — the hormonal suppression that happens with most hormonal contraceptives mean these peaks and valleys will go away, or change (19).

If you experience uncomfortable side effects from your hormonal contraceptive, talk to your health care provider. They may recommend switching to a contraception with a different chemical make-up.

Effects on mood

The normal menstrual cycle affects the brain. Special proteins on cells respond to specific chemicals for progesterone and estrogen, otherwise known as receptors and are found in many regions of the brain. These include the amygdala, which regulates aggression and fear, and the hippocampus, which has important functions for memory processing and storage (20).

Progesterone and progestin indirectly reduce the amount of serotonin, an important mood-regulating neurotransmitter, in the brain (21). It is thought that progestin from hormonal contraception may cause mood changes in users (21). However, despite the theoretical possibility, it isn’t easy to prove whether hormonal contraceptives cause mood changes.

The relationship between hormonal contraceptives and depression (21,22) has been a major area of research. In one recent study of over one million Danish women aged 15 to 34, researchers found women using hormonal contraceptives were more likely to be prescribed an antidepressant or be diagnosed with depression than women not using hormonal contraception (21). For example, women using the contraceptive patch were twice as likely to be prescribed an antidepressant as compared to women not using hormonal contraception, while women taking POCs were 1.34 times more likely (21). The risk for women taking COCs was lower than that of POCs, but still significantly higher than non-users of hormonal contraception (21).

Despite this strong evidence, the relationship between depression and hormonal contraception is not clear cut, and is likely different for different people. And even in the case of an increased risk, the overall risk may still be very small.

For people with premenstrual syndrome (PMS), premenstrual dysphoric disorder (PMDD) or major depressive disorder (MDD), hormonal contraception, particularly OCs, may cause positive changes to their mood (10,22).

Relationship to tumors and cancer

People using OCs have no change in risk (and may have a decreased risk) of fibroids, colorectal cancer, ovarian cancer and endometrial cancer (10). In contrast, OC use has been linked to the development of breast cancer (10,23). People who have used OCs for many years may be at an increased risk for breast cancer, whereas short-term use seems to have no effect on breast cancer risk (10,23). Research on this topic is mixed. Different formulations of OCs may have different effects on breast cancer risk and certain groups of people, such as those with a family history of breast cancer, may be at an increased risk in comparison with those without such a history (10,23,24).

Cardiovascular side effects

Using hormonal contraceptives comes with the potential of serious cardiovascular side effects (3,14,25–30), though such complications are rare.

Hormonal contraceptive use is also associated with changes to normal metabolic function. COC use is linked to changes in the normal levels of amino acids, fatty acids (lipids), vitamin D, inflammation markers and insulin in the body (3), in addition to changing the normal levels of estrogen and progesterone in your body. Some of these changes, such as to inflammation markers, are linked with the development of cardiovascular disease (CVD) or stroke (3). These changes seem to disappear after cessation of OC use (3).

Conversely, POCs do not seem to have a relationship with metabolic processes (3), which suggests that these changes are associated with estrogen or that progestin needs estrogen to create changes in the body.

People who take hormonal contraceptives are at increased risk of blood clots, medically referred to as thromboses, particularly in their veins (25–28). This risk may be modified by the type of estrogen and the amount of progestin (25). Strokes and heart attacks are related to the increased risk of blood clots, as both ischemic and thrombotic strokes are more likely to occur in OC users than non-OC users (29,30).

Despite increased risks, the likelihood of developing a serious medical problem from normal use of hormonal contraception is low. You can be at an increased risk but still have a low risk.

For example, the maximum risk of blood clots in OC users is estimated to be about 9 to 11 clots in 10,000 years, depending on the chemical makeup of the OC (27). While this risk is 2 to 10 times higher than that of non-OC users, the risk of developing blood clots in postpartum women in the three months following delivery is four times higher than the risk in women taking OCs (27).

There are risk factors that can increase the likelihood of developing a serious side effect from hormonal contraception. People who are obese, smoke, are older than 35 years old or have vitamin deficiencies are at an increased risk (26,27). Additionally, some people who have PCOS along with other metabolic risk factors may also be at increased risk (12,31). If you are unsure whether you are at a higher risk for the development of cardiovascular disease or blood clots while using hormonal contraception, talk to your healthcare provider.

Conclusion

For many people, hormonal contraception is safe and very effective at preventing pregnancy with minimal-to-no side effects. Many people may also experience positive side effects from hormonal contraceptives, and sometimes these positive side effects are the primary reason they take birth control.

Other people may find hormonal contraception is not a good fit for them. If you feel that your hormonal contraception may pose a risk to your health or is causing negative side effects or depression, talk to your healthcare professional. Because not all hormonal contraception has the same amount of estrogen or progestin, it is possible that you will be happier using one type or brand more than another.

Similarly, although there is thought to be no difference between the active ingredients in generic and brand name hormonal contraceptives, it is possible you may respond differently to a generic or brand name due to the inactive ingredients and so healthcare providers still recommend prescribing based on the preference of the user (32).

You are your best advocate for your health, so it is important to be honest and clear with your needs, be they pregnancy prevention or the management of other problems. Your needs may be best met by using hormonal contraception, but it may also be the case that the risks do not outweigh the benefits for you.

Using Clue can help you track symptoms that hormonal contraceptives could treat or could cause. The best way to be your own advocate is to know your body.

Clue can also help you use your hormonal contraception. You can use Clue to help remind you to take your pill, check the thread of your IUD, replace your patch or receive your hormonal injection so you are better protected against unintended pregnancy.

Are you unsure how your hormonal contraception affects you? Use Clue to start tracking your emotional and physical symptoms today.

References

1. Daniels, K., Mosher, W. D., & Jones, J. (2013). Contraceptive methods women have ever used: United States, 1982–2010. National Health Statistics Reports, 62(20).

2. Skouby, S. O. (2010). Contraceptive use and behavior in the 21st century: a comprehensive study across five European countries. The European Journal of Contraception & Reproductive Health Care, 15(sup2), S42-S53.

3. Wang, Q., Würtz, P., Auro, K., Morin-Papunen, L., Kangas, A. J., Soininen, P., … & Aalto, K. (2016). Effects of hormonal contraception on systemic metabolism: cross-sectional and longitudinal evidence. International Journal of Epidemiology, 45(5), 1445–1457.

4. Centers for Disease Control and Prevention. (2016). Reversible methods of birth control. Retrieved on November 29, 2016 from https://www.cdc.gov/reproductivehealth/contraception/

5. Rivera, R., Yacobson, I., & Grimes, D. (1999). The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices. American Journal of Obstetrics and Gynecology, 181(5), 1263–1269.

6. US Food and Drug Administration. (2016). Depo-Provera. Retrieved on November 29, 2016 from http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/012541s084lbl.pdf

7. US Food and Drug Administration. (2015). Ella. Retrieved on November 30, 2016 from http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022474s007lbl.pdf

8. Trussel, J.G. Raymond, E., & Cleland, K. (2016). Emergency Contraception: A Last Chance to Prevent Unintended Pregnancy. Retrieved from

http://ec.princeton.edu/questions/ec-review.pdf

9. World Health Organization. (2016). Emergency contraception: fact sheet. Retrieved from http://who.int/mediacentre/factsheets/fs244/en/ on December 17th, 2016.

10. Maguire, K., & Westhoff, C. (2011). The state of hormonal contraception today: established and emerging noncontraceptive health benefits. American Journal of Obstetrics and Gynecology, 205(4), S4-S8.

11. American College of Obstetricians and Gynecologists. (2010). ACOG Practice Bulletin №110: noncontraceptive uses of hormonal contraceptives. Obstet Gynecol, 115(1), 206–18.

12. Yildiz, B. O. (2008). Oral contraceptives in polycystic ovary syndrome: risk-benefit assessment. In Seminars in Reproductive Medicine (Vol. 26, №01, pp. 111–120). Thieme Medical Publishers.

13. Lam, C., & Zaenglein, A. L. (2014). Contraceptive use in acne. Clinics in Dermatology, 32(4), 502–515.

14. Barr, N. G. (2010). Managing adverse effects of hormonal contraceptives. American Family Physician, 82(12).

15. Handel, A. C., Lima, P. B., Tonolli, V. M., Miot, L. D. B., & Miot, H. A. (2014). Risk factors for facial melasma in women: a case–control study. British Journal of Dermatology, 171(3), 588–594.

16. Rosenberg, M. J., Waugh, M. S., & Meehan, T. E. (1995). Use and misuse of oral contraceptives: risk indicators for poor pill taking and discontinuation. Contraception, 51(5), 283–288.

17. Sulak, P. J., Scow, R. D., Preece, C., Riggs, M. W., & Kuehl, T. J. (2000). Hormone withdrawal symptoms in oral contraceptive users. Obstetrics & Gynecology, 95(2), 261–266.

18. Pastor, Z., Holla, K., & Chmel, R. (2013). The influence of combined oral contraceptives on female sexual desire: A systematic review. The European Journal of Contraception & Reproductive Health Care, 18(1), 27–43.

19. Caruso, S., Agnello, C., Malandrino, C., Lo Presti, L., Cicero, C., & Cianci, S. (2014). Do hormones influence women’s sex? Sexual activity over the menstrual cycle. The Journal of Sexual Medicine, 11(1), 211–221.

20. Toffoletto, S., Lanzenberger, R., Gingnell, M., Sundström-Poromaa, I., & Comasco, E. (2014). Emotional and cognitive functional imaging of estrogen and progesterone effects in the female human brain: A systematic review. Psychoneuroendocrinology, 50, 28–52.

21. Skovlund, C. W., Mørch, L. S., Kessing, L. V., & Lidegaard, Ø. (2016). Association of hormonal contraception with depression. JAMA Psychiatry, 73(11), 1154–1162.

22. Poromaa, I. S., & Segebladh, B. (2012). Adverse mood symptoms with oral contraceptives. Acta Obstetricia et Gynecologica Scandinavica, 91(4), 420–427.

23. Beaber, E. F., Malone, K. E., Tang, M. T. C., Barlow, W. E., Porter, P. L., Daling, J. R., & Li, C. I. (2014). Oral contraceptives and breast cancer risk overall and by molecular subtype among young women. Cancer Epidemiology Biomarkers & Prevention, 23(5), 755–764.

24. Freund, R., Kelsberg, G., & Safranek, S. (2014). Do oral contraceptives put women with a family history of breast cancer at increased risk?. Journal of Family Practice.

25. de Bastos, M., Stegeman, B. H., Rosendaal, F. R., Van Hylckama Vlieg, A., Helmerhorst, F. M., Stijnen, T., & Dekkers, O. M. (2014). Combined oral contraceptives: venous thrombosis. The Cochrane Library.

26. Horton, L. G., Simmons, K. B., & Curtis, K. M. (2016). Combined hormonal contraceptive use among obese women and risk for cardiovascular events: a systematic review. Contraception.

27. Committee on Gynecologic Practice. (2012). ACOG Committee Opinion Number 540: Risk of venous thromboembolism among users of drospirenone-containing oral contraceptive pills. Obstetrics and Gynecology, 120(5), 1239.

28. Tepper, N. K., Dragoman, M. V., Gaffield, M. E., & Curtis, K. M. (2016). Nonoral combined hormonal contraceptives and thromboembolism: A systematic review. Contraception. DOI: http://dx.doi.org/10.1016/j.contraception.2016.10.005

29. Roach, R. E., Helmerhorst, F. M., Lijfering, W. M., Stijnen, T., Algra, A., & Dekkers, O. M. (2015). Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke. The Cochrane Library.

30. Lidegaard, Ø., Løkkegaard, E., Jensen, A., Skovlund, C. W., & Keiding, N. (2012). Thrombotic stroke and myocardial infarction with hormonal contraception. New England Journal of Medicine, 366(24), 2257–2266.

31. Carmina, E. (2013). Oral contraceptives and cardiovascular risk in women with polycystic ovary syndrome. Journal of Endocrinological Investigation, 36(5), 358–363.

32. Committee on Gynecologic Practice. (2007). ACOG Committee Opinion №375: Brand versus generic oral contraceptives. Obstetrics and Gynecology, 110(2 Pt 1), 447.